BETA1-SELECTIVE BLOCKADE FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS: A PHASE 3, MULTI-CENTER, DOUBLE-BLINDED, RANDOMIZED PLACEBO-CONTROLLED TRIAL
Study of ATENOLOL to Prevent Bone Loss in Postmenopausal Women
Sponsor: NIH
Enrolling: Female Patients Only
IRB Number: AAAT5783
U.S. Govt. ID: NCT04905277
Contact: Mirkelis De Jesus: 212-305-7225 / md3865@cumc.columbia.edu
Additional Study Information: The goal of this study is to learn whether treatment with a safe, commonly used drug called ATENOLOL prevents bone loss in women after menopause. Who Qualifies? Healthy post-menopausal women who are between the ages of 50 and 75. You may not be eligible if you have certain medical conditions. What's Involved? If you are eligible, you will be assigned randomly to take a pill that may be either atenolol or a placebo. If you join this study, you will have 6 study visits to CUIMC over 2 years. Visit Procedures Include: measure heart rate and blood pressure, questionnaires about health and diet, a DXA scan to measure Bone Density, a Bone Quality scan to measure strength of your wrist and ankle bones, and a blood test for bone markers. All tests will be free of charge. If you join, you will be compensated for your time and travel. Learn more about participation today!
This study is closed
Investigator
Elizabeth Shane, MD
Do You Qualify?
Are you a postmenopausal woman? Yes No
Are you between the ages of 50-75? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Mirkelis De Jesus
md3865@cumc.columbia.edu
212-305-7225